<DOC>
	<DOCNO>NCT02889809</DOCNO>
	<brief_summary>There regulatory requirement evaluate extent reduction ( ) growth velocity associate inhaled corticosteroid ( ICS ) contain product administer child , end Food Drug Administration ( FDA ) regulatory guidance . This randomised , single-blind ( run-in period ) /double-blind ( treatment period ) , parallel group , placebo control , multicentre study assess effect daily ( OD ) inhale fluticasone furoate ( FF ) 50 microgram ( mcg ) growth velocity prepubertal asthmatic child background therapy open-label montelukast . This study conduct total duration approximately 76 week : 16-week run-in period ( single-blind placebo inhaler ) , 52-week double-blind treatment period ( inhaled FF 50 mcg /placebo administer OD morning 52 week ) 8-week follow-up period . The purpose study evaluate magnitude effect ( level precision ) growth velocity prepubertal asthmatic paediatric subject ( age 5 &lt; 9 year ) follow administration OD inhale FF 50 mcg one year . This study fulfill European Union ( EU ) United States ( US ) regulatory requirement evaluation potential growth suppression child .</brief_summary>
	<brief_title>Effects Orally Inhaled Fluticasone Furoate Growth Velocity Prepubertal , Paediatric Subjects With Asthma Over Year</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Male female subject . Age : Males 5 &lt; 9 year old ; Females 5 &lt; 8 year old . Subjects must prepubertal ( Tanner Stage 1 ) . Height centile 3 % 97 % base local growth chart . Subjects body weight body mass index 3rd 97th centile base United State ( US ) Centres Disease Control Prevention ( CDC ) standard statistic local standard outside US . A documented history symptom consistent diagnosis asthma least 6 month prior Visit 1 . A prebronchodilatory forced expiratory flow 1 second ( FEV1 ) Visit 1 ( Screening ) &gt; =60 % &lt; =95 % predict . There short act beta 2 agonist ( SABA ) use within 4 hour measurement . Able replace current SABA treatment study supply rescue albuterol/salbutamol provide Visit 1 use need duration study . A childhood asthma control test ( cACT ) score &gt; 19 . Subjects require least one course corticosteroid asthma ( inhaled oral ) past year . There must ICS use within 6 week Visit 1 ( Screening ) . There must oral corticosteroid use within 12 week Visit 1 ( Screening ) . Using one follow asthma therapy prior entry study : Short act betaagonist ( SABA ) inhaler alone ( example give [ e.g . ] salbutamol ) need basis and/or regular nonICS controller medication asthma ( e.g . cromones leukotriene receptor antagonist ) . Written informed consent least one parent/care giver ( legal guardian ) accompany inform assent subject ( subject able provide assent ) prior admission study . If applicable , subject must able willing give assent take part study accord local requirement . The study investigator accountable determine child 's capacity assent participation research study , take consideration standard set responsible Independent Ethics Committee ( IEC ) . Subject legal guardian ( ) understand must comply study medication administration regimen study assessment include record symptom score rescue albuterol/salbutamol use , attend study visit , accessible telephone . Growth Criteria : Any previous current condition affect growth , include sleep disorder , endocrine disorder , skeletal dysplasia , Turner Noonan syndrome , Marfan , BeckwithWiedeman Sotos syndromes , Klinefelter 's syndrome , coeliac disease , inflammatory bowel diseases renal failure significant abnormality medical condition identify screen medical assessment ( include serious psychological disorder ) likely interfere conduct study . Subjects premature adrenarche . A child unable stand , find stand difficult due illness physical disability exclude . Disease Criteria : Subjects history asthma exacerbation require use systemic corticosteroid ( tablet , suspension , injection ) least 3 day use depot corticosteroid injection within 3 month require hospitalisation asthma ( within 6 month ) prior screen . Culturedocumented suspected bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week Visit 1 lead change asthma management , opinion Investigator , expect affect subject 's asthma status subject 's ability participate study . Clinical visual evidence candidiasis Visit 1 ( Screening ) . Any significant abnormality medical condition identify screen medical assessment Investigator 's opinion , preclude entry study due risk subject may interfere outcome study . General : Prior use medication treatment might affect growth include , limited : amphetamine , anticonvulsant , biphosphonates , calcitonin , calcitriol , erythropoietin , growth hormone , methylphenidate , phosphate binder , antithyroid drug ( e.g. , Methimazole ) thyroid hormone . Use prohibit medication list study protocol . Hypersensitivity : Known hypersensitivity corticosteroid , leukotrienes , excipients ELLIPTA ( ELLIPTA Glaxosmithkline own trademark dry powder inhaler ) inhaler study tablet . Milk Protein Allergy : History severe milk protein allergy . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure 4 investigational medicinal product within 12 month prior first dose day . Children immediate family member participate Investigator , subInvestigator , study coordinator , employee participate Investigator . The Parent Guardian history know suspected psychiatric disease , intellectual deficiency , substance abuse condition ( e.g . inability read , comprehend write ) may affect : validity consent participate study ; adequate supervision subject study ; compliance subject study medication study procedure ( e.g . completion daily diary , attend schedule clinic visit ) ; subject safety wellbeing . Children care : Children ward government state eligible participation study .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Growth Velocity</keyword>
	<keyword>Prepubertal</keyword>
	<keyword>Asthma</keyword>
	<keyword>Paediatric</keyword>
</DOC>